MA54601A - Nouvelles protéines de liaison multi-spécifiques à base de pseudofab - Google Patents

Nouvelles protéines de liaison multi-spécifiques à base de pseudofab

Info

Publication number
MA54601A
MA54601A MA054601A MA54601A MA54601A MA 54601 A MA54601 A MA 54601A MA 054601 A MA054601 A MA 054601A MA 54601 A MA54601 A MA 54601A MA 54601 A MA54601 A MA 54601A
Authority
MA
Morocco
Prior art keywords
pseudofab
new
specific binding
binding proteins
based multi
Prior art date
Application number
MA054601A
Other languages
English (en)
Inventor
Christian Beil
Karl-Christian Engel
Gerhard Hessler
Soraya Hoelper
Christian Lange
Thomas Langer
Cendrine Lemoine
Wulf-Dirk Leuschner
Bruederle Sevim Oezguer
Ercole Rao
Nadja Spindler
Sandra Weil
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18306840.2A external-priority patent/EP3674319A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA54601A publication Critical patent/MA54601A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA054601A 2018-12-24 2019-12-23 Nouvelles protéines de liaison multi-spécifiques à base de pseudofab MA54601A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306840.2A EP3674319A1 (fr) 2018-12-24 2018-12-24 Protéines de liaison multispécifiques à base de pseudofab
EP19305813 2019-06-21

Publications (1)

Publication Number Publication Date
MA54601A true MA54601A (fr) 2022-03-30

Family

ID=69174547

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054601A MA54601A (fr) 2018-12-24 2019-12-23 Nouvelles protéines de liaison multi-spécifiques à base de pseudofab

Country Status (16)

Country Link
US (2) US11739160B2 (fr)
EP (1) EP3902825A1 (fr)
JP (1) JP7734075B2 (fr)
KR (1) KR20220015369A (fr)
CN (1) CN114885609B (fr)
AU (1) AU2019416895A1 (fr)
BR (1) BR112021012337A2 (fr)
CA (1) CA3124770A1 (fr)
CO (1) CO2021009025A2 (fr)
IL (2) IL284317B2 (fr)
MA (1) MA54601A (fr)
MX (1) MX2021007677A (fr)
PH (1) PH12021500028A1 (fr)
SG (1) SG11202106393SA (fr)
TW (1) TW202041534A (fr)
WO (1) WO2020136564A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7734075B2 (ja) 2018-12-24 2025-09-04 サノフイ 疑似ｆａｂベースの多重特異性結合タンパク質
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
CN115536749A (zh) * 2021-06-29 2022-12-30 三生国健药业（上海）股份有限公司 三特异性抗体、其制备方法和用途
WO2024206669A2 (fr) * 2023-03-29 2024-10-03 Virtuoso Binco, Inc. Anticorps pour cibler cd47 et b7h3 et leurs méthodes d'utilisation
WO2025262304A1 (fr) * 2024-06-20 2025-12-26 Sanofi Protéines de liaison comprenant un anticorps inhibiteur de point de contrôle ou un fragment de celui-ci, et des multimères de ligand de la superfamille des récepteurs du tnf à chaîne unique

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5732168A (en) 1995-10-31 1998-03-24 Hewlett Packard Company Thermal optical switches for light
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
AU2001270609A1 (en) * 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US8420783B2 (en) 2004-12-08 2013-04-16 Immunomedics, Inc. Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
MX2011006870A (es) 2008-12-23 2011-07-19 Genentech Inc Variantes de inmunoglobulina con union alterada a proteina a.
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
AU2010336277B2 (en) 2009-12-25 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Polypeptide modification method for purifying polypeptide multimers
WO2011117653A1 (fr) * 2010-03-25 2011-09-29 Ucb Pharma S.A. Molécules de dvd-lg stabilisées par un disulfure
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (fr) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Protéines hétérodimériques et leurs procédés de production et de purification
WO2012023053A2 (fr) 2010-08-16 2012-02-23 Novimmune S.A. Procédé de production d'anticorps multispécifiques et multivalents
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
ES2767135T3 (es) 2011-10-19 2020-06-16 Novimmune Sa Métodos para purificar anticuerpos
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
EP3517548A1 (fr) 2012-03-13 2019-07-31 NovImmune S.A. Anticorps bispécifiques facilement isolés avec un format natif d'immunoglobuline
WO2014004586A1 (fr) 2012-06-25 2014-01-03 Zymeworks Inc. Processus et procédés pour la fabrication efficace d'anticorps asymétriques hautement purs dans des cellules de mammifère
US20150239991A1 (en) 2012-09-25 2015-08-27 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
EP2938637A2 (fr) 2012-12-28 2015-11-04 AbbVie Inc. Compositions protéiques à liaison multivalente
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
EP3041865A2 (fr) 2013-09-03 2016-07-13 NovImmune S.A. Molécules de liaison bispécifiques facilement isolées au format natif, mais possédant des régions constantes mutées
CA2943299A1 (fr) * 2014-04-11 2015-10-15 Medimmune, Llc Anticorps anti-her2 bispecifiques
WO2015173756A2 (fr) * 2014-05-16 2015-11-19 Pfizer Inc. Anticorps bispécifiques
US20170210818A1 (en) 2014-06-06 2017-07-27 The California Institute For Biomedical Research Constant region antibody fusion proteins and compositions thereof
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
WO2016087416A1 (fr) * 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Anticorps multispécifiques
CN107922476A (zh) 2015-03-13 2018-04-17 诺夫免疫股份有限公司 纯化双特异性抗体的方法
EP3319996B1 (fr) 2015-07-09 2024-01-03 Genmab A/S Anticorps bispécifiques et multispécifiques et procédé pour l'isolement de ceux-ci
EP3443006B1 (fr) 2016-04-13 2023-08-02 Sanofi Protéines de liaison trispécifiques et/ou trivalentes
CN117843810A (zh) * 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
JP7734075B2 (ja) 2018-12-24 2025-09-04 サノフイ 疑似ｆａｂベースの多重特異性結合タンパク質
EP3674319A1 (fr) 2018-12-24 2020-07-01 Sanofi Protéines de liaison multispécifiques à base de pseudofab
WO2021198204A1 (fr) * 2020-03-30 2021-10-07 Sanofi Domaines ch2 divisés
AU2022215712A1 (en) * 2021-02-07 2023-09-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bispecific antibody

Also Published As

Publication number Publication date
PH12021500028A1 (en) 2022-05-02
IL284317B1 (en) 2025-06-01
SG11202106393SA (en) 2021-07-29
JP2024504880A (ja) 2024-02-02
IL319262A (en) 2025-04-01
WO2020136564A1 (fr) 2020-07-02
CN114885609B (zh) 2026-02-17
CO2021009025A2 (es) 2021-12-10
IL284317B2 (en) 2025-10-01
CA3124770A1 (fr) 2020-07-02
AU2019416895A2 (en) 2021-09-09
AU2019416895A1 (en) 2021-08-12
TW202041534A (zh) 2020-11-16
BR112021012337A2 (pt) 2021-09-14
CN114885609A (zh) 2022-08-09
US11739160B2 (en) 2023-08-29
US20230391888A1 (en) 2023-12-07
IL284317A (en) 2021-08-31
EP3902825A1 (fr) 2021-11-03
US20200255540A1 (en) 2020-08-13
JP7734075B2 (ja) 2025-09-04
MX2021007677A (es) 2021-12-10
KR20220015369A (ko) 2022-02-08

Similar Documents

Publication Publication Date Title
EP4225364A4 (fr) Protéines f hmpv stabilisées par préfusion
IL281962A (en) Il-12 heterodimeric fc-fusion proteins
EP3802581A4 (fr) Protéines de liaison multispécifiques et améliorations de celles-ci
MA53616A (fr) Protéines bispécifiques modifiées
EP3655432A4 (fr) Protéines de liaison 1
EP3819300A4 (fr) Composition thérapeutique à base de biomarqueurs
PT3649151T (pt) Proteínas de suporte
EP3717505A4 (fr) Protéines de liaison à l'adn modifiées
EP3917542A4 (fr) Protéines de liaison multispécifiques
EP3352760A4 (fr) Polypeptides de liaison à cd3
EP3307266A4 (fr) Nouvelles polythérapies à base de cannabinoïdes pour le myélome multiple (mm)
EP3802551A4 (fr) Inhibiteurs de protéine de liaison à la pénicilline
EP3402519A4 (fr) Constructions de liaison à l'antigène immunomodulateur multispécifique
DK3784047T3 (da) Gærproteiner
EP3806645A4 (fr) Composition nutritionnelle à base de protéine de pois intacte
EP3864235C0 (fr) Sous-couche
DK3737402T5 (da) Modificeret protein
IL290878A (en) Protein based cannabis compositions
EP3802565A4 (fr) Polypeptides
EP3514167A4 (fr) Peptide de liaison à la thrombospondine 1
EP4022337C0 (fr) Détermination de position
EP4159872C0 (fr) Marquage de l'adn
DK4034170T3 (da) Tgf-beta-polypeptider
DK3840767T3 (da) Peptider
IL284317A (en) Pseudofab-based multispecific binding proteins